Article ; Online: Quantification and Explanation of the Variability of First-Dose Amikacin Concentrations in Critically Ill Patients Admitted to the Emergency Department: A Population Pharmacokinetic Analysis.
European journal of drug metabolism and pharmacokinetics
2021 Volume 46, Issue 5, Page(s) 653–663
Abstract: Background: There may be a difference between the determinants of amikacin exposure in emergency department (ED) versus intensive care (ICU) patients, and the peak amikacin concentration varies widely between patients. Moreover, when the first dose of ... ...
Abstract | Background: There may be a difference between the determinants of amikacin exposure in emergency department (ED) versus intensive care (ICU) patients, and the peak amikacin concentration varies widely between patients. Moreover, when the first dose of antimicrobials is administered to septic patients admitted to the ED, fluid resuscitation and vasopressors have just been initiated. Nevertheless, population pharmacokinetic modelling data for amikacin in ED patients are unavailable. Objective: The aim of this study was to quantify the interindividual variability (IIV) in the pharmacokinetics of amikacin in patients admitted to the ED and to identify the patient characteristics that explain this IIV. Methods: Patients presenting at the ED with severe sepsis or septic shock were randomly assigned to receive amikacin 25 mg/kg or 15 mg/kg intravenously. Blood samples were collected at 1, 6 and 24 h after the onset of the first amikacin infusion. Data were analysed using nonlinear mixed-effects modelling. Results: A two-compartment population pharmacokinetic model was developed based on 279 amikacin concentrations from 97 patients. The IIV in clearance (CL) and central distribution volume (V Conclusion: The IIV of amikacin pharmacokinetics in ED patients is large. Higher doses may be considered in patients with low serum sodium levels, low total protein levels, or a high fluid balance. Trial registration: ClinicalTrials.gov ID: NCT02365272. |
---|---|
MeSH term(s) | Aged ; Aged, 80 and over ; Amikacin/administration & dosage ; Amikacin/pharmacokinetics ; Anti-Bacterial Agents/administration & dosage ; Anti-Bacterial Agents/pharmacokinetics ; Critical Illness ; Dose-Response Relationship, Drug ; Emergency Service, Hospital ; Female ; Humans ; Infusions, Intravenous ; Male ; Middle Aged ; Models, Biological ; Prospective Studies ; Sepsis/drug therapy ; Shock, Septic/drug therapy ; Tissue Distribution |
Chemical Substances | Anti-Bacterial Agents ; Amikacin (84319SGC3C) |
Language | English |
Publishing date | 2021-07-23 |
Publishing country | France |
Document type | Journal Article ; Randomized Controlled Trial |
ZDB-ID | 196729-0 |
ISSN | 2107-0180 ; 0398-7639 ; 0378-7966 |
ISSN (online) | 2107-0180 |
ISSN | 0398-7639 ; 0378-7966 |
DOI | 10.1007/s13318-021-00698-w |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 1236: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.